Bacteriophage research and therapy


Common use of antibiotics in the developed world has resulted in the emergence of bacterial strains, which are highly resistant to virtually all available antimicrobial agents (Nature 2002, 418, 469). As a result, in most infections induced by such bacteria even intensive antibiotic therapy is ineffective. This creates a serious therapeutic problem. Therefore, we observe a growing interest in the use of bacteriophages in medical practice. Since 1980 the specific bacteriophages have been used in our Laboratory for the treatment of over 1500 patients with suppurative bacterial infections, in which a routine antibiotic therapy failed. The results obtained so far showed that phage therapy is safe and highly effective (the majority of patients were cured). Phage therapy may be applied to all patients from whom isolated bacterial strains show full sensitivity to specific phages. Of particular importance is that two pathogens: Staphylococcus aureus and Pseudomonas aeruginosa, which most frequently cause infections, were found to be sensitive to specific phages in more than 80% of cases.

Our Laboratory possesses over 300 specific bacteriophage strains active against Staphylococcus aureus, Escherichia, Klebsiella, Enterobacter, Proteus and Pseudomonas.

We offer:

  • isolation and identification of bacterial strains from the specimens of patients,
  • determination of sensitivity of the isolated strains to specific bacteriophages,
  • preparation of phage lysates for a therapeutic treatment.


The indications of the range of phage therapy are as follows: postoperative infections, mucopurulent bronchitis, furunculosis*, otitis media, sinusitis, abscesses cutis and decubitus ulcer, pyogenic arthritis, osteomyelitis, suppurative infections after injuries of soft tissue, such as contusions, burns, pyogenic infection after bone fractures, chronic infections of the urinary tract, bacterial prostatitis.

The majority of patients were cured

Detailed information can be obtained from Prof. A. Gorski and Dr B. Weber-Dabrowska, e-mail: agorski@ikp.pl